Oral small molecule GLP-1 receptor agonist
Lotiglipron 160 mg tablet once daily
LOTI_PO_160MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.73 (0.05 to 4.61) | 0.58 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.55 (0.48 to 4.51) | 0.52 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.93 (1.35 to 6.35) | 0.46 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.38 (1.05 to 9.88) | 0.43 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.72 (0.21 to 1.93) | 0.79 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.38 (0.36 to 4.13) | 0.56 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.94 (0.05 to 15.25) | 0.45 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.54 (0.01 to 25.70) | 0.53 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.74 (0.06 to 5.05) | 0.61 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.37 (0.38 to 4.26) | 0.60 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.22 (0.97 to 4.84) | 0.71 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.89 (0.81 to 10.01) | 0.63 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.53 (0.14 to 1.58) | 0.88 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.01 (0.25 to 3.66) | 0.72 |